NR 568 ADVANCED PHARMACOLOGY FOR
AGPCNP - Final Weeks 5-8 - Chamberlain -
2026/2027 - 100Q Real
Weeks 5-6 Endocrine Diabetes
Description: T2DM ADA metformin first-line SGLT2i GLP-1 RA ASCVD CKD insulin basal-bolus hypo Rule 15 thyroid
levo empty stomach methimazole agranulocytosis desmopressin central DI.
Weeks 6 Antimicrobials Respiratory UTI
Description: CAP amox doxy macrolide MRSA vanco linezolid Pseudomonas coverage COPD exacerbation UTI
cystitis nitrofurantoin TMP-SMX fosfomycin pyelo cipro FQ black box tendon neuropathy nitrofurantoin CrCl<30 avoid
pyelo.
Weeks 7 Respiratory Asthma COPD Flu TB
Description: Asthma ICS suppress inflammation LABA never alone SABA albuterol beta2 rescue LAMA tiotropium
COPD oseltamivir 48h latent TB 4R rifampin.
Weeks 7-8 GI GERD PUD IBS
Description: PPI H+/K+ ATPase cimetidine CYP inhibitor famotidine minimal metoclopramide tardive dyskinesia
loperamide mu opioid avoid bloody H pylori bismuth quadruple IBS-D alosetron eluxadoline IBS-C linaclotide GC-C
ondansetron 5-HT3 QT.
Week 8 Cardiac Lipids Anticoagulation
Description: Statins HMG-CoA reductase LFT CK pregnancy contraindicated ezetimibe NPC1L1 PCSK9 warfarin
vitamin K antagonist reversal vitamin K PCC DOACs apixaban 2 of 3 dose reduction HIT argatroban.
Page 1 - NR568 Weeks 5-8
,Question 1: 65yo T2DM A1c 8.2% metformin BID eGFR 58 ASCVD best add-on?
A. Add SGLT2i empagliflozin ASCVD benefit
B. Add glipizide
C. Add pioglitazone
D. Stop metformin
CORRECT ANSWER: A. Add SGLT2i empagliflozin ASCVD benefit
RATIONALE:
ADA ASCVD+T2DM eGFR>45 add SGLT2i CV benefit or GLP-1 RA. SGLT2i renal protective.
Question 2: SGLT2 mechanism?
A. Inhibit glucose reabsorption proximal tubule SGLT2 glucosuria
B. Increase insulin
C. Decrease hepatic gluconeogenesis
D. Delay carb absorption
CORRECT ANSWER: A. Inhibit glucose reabsorption proximal tubule SGLT2 glucosuria
RATIONALE:
SGLT2i block SGLT2 proximal tubule increase urinary glucose osmotic diuresis A1c ~0.7% weight loss BP CV renal
benefit.
Question 3: GLP-1 RA contraindication?
A. Personal/family medullary thyroid carcinoma MEN2
B. HTN
C. Hyperlipidemia
D. Obesity
CORRECT ANSWER: A. Personal/family medullary thyroid carcinoma MEN2
RATIONALE:
GLP-1 RA boxed warning contraindicated medullary thyroid carcinoma MEN2 rodent C-cell tumor.
Question 4: Metformin mechanism max dose?
A. Decreases hepatic gluconeogenesis improves insulin sensitivity max 2550 mg/day
B. Increases insulin
C. Increases urinary glucose
D. Delays absorption
CORRECT ANSWER: A. Decreases hepatic gluconeogenesis improves insulin sensitivity max 2550
mg/day
RATIONALE:
Metformin biguanide decreases hepatic glucose production max 2550 IR 2000 ER common hold if eGFR<30.
Question 5: Longest duration insulin no peak?
A. Glargine Lantus 24 hr basal no peak
B. Regular
C. Lispro
D. NPH
CORRECT ANSWER: A. Glargine Lantus 24 hr basal no peak
RATIONALE:
Glargine U100 basal ~24h flat. Degludec >42h. NPH intermediate peak 4-8h.
Page 2 - NR568 Weeks 5-8
, Page 3 - NR568 Weeks 5-8
AGPCNP - Final Weeks 5-8 - Chamberlain -
2026/2027 - 100Q Real
Weeks 5-6 Endocrine Diabetes
Description: T2DM ADA metformin first-line SGLT2i GLP-1 RA ASCVD CKD insulin basal-bolus hypo Rule 15 thyroid
levo empty stomach methimazole agranulocytosis desmopressin central DI.
Weeks 6 Antimicrobials Respiratory UTI
Description: CAP amox doxy macrolide MRSA vanco linezolid Pseudomonas coverage COPD exacerbation UTI
cystitis nitrofurantoin TMP-SMX fosfomycin pyelo cipro FQ black box tendon neuropathy nitrofurantoin CrCl<30 avoid
pyelo.
Weeks 7 Respiratory Asthma COPD Flu TB
Description: Asthma ICS suppress inflammation LABA never alone SABA albuterol beta2 rescue LAMA tiotropium
COPD oseltamivir 48h latent TB 4R rifampin.
Weeks 7-8 GI GERD PUD IBS
Description: PPI H+/K+ ATPase cimetidine CYP inhibitor famotidine minimal metoclopramide tardive dyskinesia
loperamide mu opioid avoid bloody H pylori bismuth quadruple IBS-D alosetron eluxadoline IBS-C linaclotide GC-C
ondansetron 5-HT3 QT.
Week 8 Cardiac Lipids Anticoagulation
Description: Statins HMG-CoA reductase LFT CK pregnancy contraindicated ezetimibe NPC1L1 PCSK9 warfarin
vitamin K antagonist reversal vitamin K PCC DOACs apixaban 2 of 3 dose reduction HIT argatroban.
Page 1 - NR568 Weeks 5-8
,Question 1: 65yo T2DM A1c 8.2% metformin BID eGFR 58 ASCVD best add-on?
A. Add SGLT2i empagliflozin ASCVD benefit
B. Add glipizide
C. Add pioglitazone
D. Stop metformin
CORRECT ANSWER: A. Add SGLT2i empagliflozin ASCVD benefit
RATIONALE:
ADA ASCVD+T2DM eGFR>45 add SGLT2i CV benefit or GLP-1 RA. SGLT2i renal protective.
Question 2: SGLT2 mechanism?
A. Inhibit glucose reabsorption proximal tubule SGLT2 glucosuria
B. Increase insulin
C. Decrease hepatic gluconeogenesis
D. Delay carb absorption
CORRECT ANSWER: A. Inhibit glucose reabsorption proximal tubule SGLT2 glucosuria
RATIONALE:
SGLT2i block SGLT2 proximal tubule increase urinary glucose osmotic diuresis A1c ~0.7% weight loss BP CV renal
benefit.
Question 3: GLP-1 RA contraindication?
A. Personal/family medullary thyroid carcinoma MEN2
B. HTN
C. Hyperlipidemia
D. Obesity
CORRECT ANSWER: A. Personal/family medullary thyroid carcinoma MEN2
RATIONALE:
GLP-1 RA boxed warning contraindicated medullary thyroid carcinoma MEN2 rodent C-cell tumor.
Question 4: Metformin mechanism max dose?
A. Decreases hepatic gluconeogenesis improves insulin sensitivity max 2550 mg/day
B. Increases insulin
C. Increases urinary glucose
D. Delays absorption
CORRECT ANSWER: A. Decreases hepatic gluconeogenesis improves insulin sensitivity max 2550
mg/day
RATIONALE:
Metformin biguanide decreases hepatic glucose production max 2550 IR 2000 ER common hold if eGFR<30.
Question 5: Longest duration insulin no peak?
A. Glargine Lantus 24 hr basal no peak
B. Regular
C. Lispro
D. NPH
CORRECT ANSWER: A. Glargine Lantus 24 hr basal no peak
RATIONALE:
Glargine U100 basal ~24h flat. Degludec >42h. NPH intermediate peak 4-8h.
Page 2 - NR568 Weeks 5-8
, Page 3 - NR568 Weeks 5-8
